Dr. Gary I. Sinclair, MD
Internal Medicine (Internal Medicine Physician)
- Medicare participating
At a glance
- Years since graduation
- 32
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 36
Licensed in Texas since 2000, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
TX license L0936 (first issued 2000; active) -
Infectious Disease Physician
TX license L0936 (first issued 2000; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Aids Arms, Inc. (17 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 36
- Services billed
- 234
- Patients’ average age
- 63
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 85 | 34 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Rosuvastatin Calcium Other prescribers in Dallas, TX | 339 |
| Symtuza (darunavir/cob/emtri/tenof alaf) | 292 |
| Amlodipine Besylate Other prescribers in Dallas, TX | 176 |
| Atorvastatin Calcium Other prescribers in Dallas, TX | 175 |
| Losartan Potassium Other prescribers in Dallas, TX | 143 |
| Famotidine Other prescribers in Dallas, TX | 140 |
| Tivicay (dolutegravir sodium) | 136 |
| Dovato (dolutegravir sodium/lamivudine) | 134 |
| Gabapentin Other prescribers in Dallas, TX | 128 |
| Fluticasone Propionate Other prescribers in Dallas, TX | 122 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 206 payments worth $88,160 in total to this clinician.
| Viiv Healthcare Company | $67,553 |
|---|---|
| Merck Sharp & Dohme LLC | $9,062 |
| Theratechnologies Inc. | $8,876 |
| Gilead Sciences, Inc. | $2,327 |
| EMD Serono, Inc. | $147 |
| Novo Nordisk Inc | $116 |
| Pfizer Inc. | $50.60 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.48 |
| Compensation for services other than consulting (speaking, faculty) | $58,520 |
|---|---|
| Travel and Lodging | $13,295 |
| Honoraria | $8,210 |
| Food and Beverage | $6,385 |
| Consulting Fee | $1,750 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Viiv Healthcare Company Apr 3, 2025 | Compensation for services other than consulting (speaking, faculty) CABENUVA · HIV | $7,150 |
| Viiv Healthcare Company Nov 26, 2025 | Compensation for services other than consulting (speaking, faculty) CABENUVA · HIV | $7,150 |
| Merck Sharp & Dohme LLC Feb 5, 2025 | Compensation for services other than consulting (speaking, faculty) PIFELTRO · INFECTIOUS DISEASE | $5,220 |
| Theratechnologies Inc. Dec 15, 2025 | Honoraria EGRIFTA · HIV | $3,960 |
| Viiv Healthcare Company Jan 3, 2025 | Compensation for services other than consulting (speaking, faculty) APRETUDE · HIV | $3,900 |
| Viiv Healthcare Company Mar 14, 2025 | Compensation for services other than consulting (speaking, faculty) APRETUDE · HIV | $3,900 |
| Viiv Healthcare Company Sep 2, 2025 | Compensation for services other than consulting (speaking, faculty) APRETUDE · HIV | $3,900 |
| Viiv Healthcare Company Mar 20, 2025 | Compensation for services other than consulting (speaking, faculty) CABENUVA · HIV | $2,600 |
| Viiv Healthcare Company Apr 22, 2025 | Compensation for services other than consulting (speaking, faculty) CABENUVA · HIV | $2,600 |
| Viiv Healthcare Company Jun 24, 2025 | Compensation for services other than consulting (speaking, faculty) CABENUVA · HIV | $2,600 |
All 67 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Theratechnologies Inc. Dec 15, 2025 | Honoraria EGRIFTA · HIV | $3,960 |
| Theratechnologies Inc. Dec 15, 2025 | Travel and Lodging EGRIFTA · HIV · travel to Dallas, TX | $76.80 |
| Merck Sharp & Dohme LLC Dec 3, 2025 | Travel and Lodging INFECTIOUS DISEASE · travel to Chicago, IL · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $468 |
| Merck Sharp & Dohme LLC Dec 3, 2025 | Travel and Lodging INFECTIOUS DISEASE · travel to Chicago, IL · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $232 |
| Merck Sharp & Dohme LLC Dec 3, 2025 | Travel and Lodging INFECTIOUS DISEASE · travel to Chicago, IL · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $185 |
| Merck Sharp & Dohme LLC Dec 3, 2025 | Travel and Lodging INFECTIOUS DISEASE · travel to Chicago, IL · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $107 |
| Viiv Healthcare Company Nov 26, 2025 | Compensation for services other than consulting (speaking, faculty) CABENUVA · HIV | $7,150 |
| Viiv Healthcare Company Nov 24, 2025 | Compensation for services other than consulting (speaking, faculty) CABENUVA · HIV | $1,300 |
| Viiv Healthcare Company Nov 7, 2025 | Travel and Lodging CABENUVA · HIV · travel to Dallas, TX | $238 |
| Viiv Healthcare Company Oct 18, 2025 | Travel and Lodging travel to Atlanta, GA · in-kind | $75.08 |
| Theratechnologies Inc. Oct 16, 2025 | Honoraria EGRIFTA · HIV | $2,000 |
| Viiv Healthcare Company Oct 7, 2025 | Travel and Lodging travel to Atlanta, GA · in-kind | $238 |
| Viiv Healthcare Company Sep 15, 2025 | Compensation for services other than consulting (speaking, faculty) APRETUDE · HIV | $2,600 |
| Viiv Healthcare Company Sep 8, 2025 | Compensation for services other than consulting (speaking, faculty) APRETUDE · HIV | $1,300 |
| Viiv Healthcare Company Sep 8, 2025 | Travel and Lodging travel to Atlanta, GA · in-kind | $298 |
| Viiv Healthcare Company Sep 8, 2025 | Travel and Lodging travel to Atlanta, GA · in-kind | $31.41 |
| Viiv Healthcare Company Sep 2, 2025 | Compensation for services other than consulting (speaking, faculty) APRETUDE · HIV | $3,900 |
| Viiv Healthcare Company Sep 2, 2025 | Compensation for services other than consulting (speaking, faculty) APRETUDE · HIV | $2,600 |
| Viiv Healthcare Company Aug 25, 2025 | Travel and Lodging APRETUDE · HIV · travel to San Francisco, CA | $152 |
| Viiv Healthcare Company Aug 25, 2025 | Travel and Lodging APRETUDE · HIV · travel to Portland, OR | $102 |
| Viiv Healthcare Company Aug 7, 2025 | Travel and Lodging APRETUDE · HIV · travel to San Francisco, CA · in-kind | $830 |
| Viiv Healthcare Company Aug 7, 2025 | Travel and Lodging APRETUDE · HIV · travel to San Francisco, CA · in-kind | $268 |
| Viiv Healthcare Company Aug 6, 2025 | Travel and Lodging APRETUDE · HIV · travel to Portland, OR · in-kind | $1,202 |
| Viiv Healthcare Company Aug 6, 2025 | Travel and Lodging APRETUDE · HIV · travel to Portland, OR · in-kind | $347 |
| Theratechnologies Inc. Jul 22, 2025 | Honoraria EGRIFTA · HIV | $2,250 |
| Viiv Healthcare Company Jun 26, 2025 | Travel and Lodging travel to Miami, FL · in-kind | $298 |
| Viiv Healthcare Company Jun 24, 2025 | Compensation for services other than consulting (speaking, faculty) CABENUVA · HIV | $2,600 |
| Viiv Healthcare Company Jun 13, 2025 | Travel and Lodging CABENUVA · HIV · travel to Houston, TX | $344 |
| Viiv Healthcare Company May 29, 2025 | Travel and Lodging CABENUVA · HIV · travel to Houston, TX · in-kind | $400 |
| Viiv Healthcare Company May 8, 2025 | Travel and Lodging travel to Miami, FL · in-kind | $496 |
| Viiv Healthcare Company May 8, 2025 | Travel and Lodging travel to Miami, FL · in-kind | $97.97 |
| Viiv Healthcare Company May 8, 2025 | Travel and Lodging travel to Miami, FL · in-kind | $31.41 |
| Viiv Healthcare Company May 8, 2025 | Travel and Lodging travel to Miami, FL · in-kind | $31.41 |
| Viiv Healthcare Company May 5, 2025 | Compensation for services other than consulting (speaking, faculty) CABENUVA · HIV | $2,600 |
| Viiv Healthcare Company Apr 29, 2025 | Compensation for services other than consulting (speaking, faculty) APRETUDE · HIV | $2,600 |
| Viiv Healthcare Company Apr 25, 2025 | Travel and Lodging APRETUDE · HIV · travel to Plano, TX | $35.70 |
| Viiv Healthcare Company Apr 22, 2025 | Compensation for services other than consulting (speaking, faculty) CABENUVA · HIV | $2,600 |
| Viiv Healthcare Company Apr 10, 2025 | Travel and Lodging CABENUVA · HIV · travel to Shreveport, LA · in-kind | $1,200 |
| Viiv Healthcare Company Apr 9, 2025 | Travel and Lodging CABENUVA · HIV · travel to Paris, TX | $165 |
| Merck Sharp & Dohme LLC Apr 9, 2025 | Travel and Lodging INFECTIOUS DISEASE · travel to Houston, TX Company’s descriptionProvided as part of a clinical research engagement. | $53.14 |
| Viiv Healthcare Company Apr 3, 2025 | Compensation for services other than consulting (speaking, faculty) CABENUVA · HIV | $7,150 |
| Merck Sharp & Dohme LLC Mar 27, 2025 | Travel and Lodging INFECTIOUS DISEASE · travel to Houston, TX · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $156 |
| Merck Sharp & Dohme LLC Mar 27, 2025 | Travel and Lodging INFECTIOUS DISEASE · travel to Houston, TX · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $140 |
| Merck Sharp & Dohme LLC Mar 26, 2025 | Travel and Lodging INFECTIOUS DISEASE · travel to Houston, TX · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $297 |
| Merck Sharp & Dohme LLC Mar 26, 2025 | Travel and Lodging INFECTIOUS DISEASE · travel to Houston, TX · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $260 |
| Viiv Healthcare Company Mar 25, 2025 | Compensation for services other than consulting (speaking, faculty) CABENUVA · HIV | $2,600 |
| Viiv Healthcare Company Mar 20, 2025 | Compensation for services other than consulting (speaking, faculty) CABENUVA · HIV | $2,600 |
| Viiv Healthcare Company Mar 14, 2025 | Compensation for services other than consulting (speaking, faculty) APRETUDE · HIV | $3,900 |
| Viiv Healthcare Company Mar 14, 2025 | Travel and Lodging APRETUDE · HIV · travel to Houston, TX | $198 |
| Viiv Healthcare Company Mar 14, 2025 | Travel and Lodging CABENUVA · HIV · travel to Dallas, TX | $144 |
| Viiv Healthcare Company Mar 11, 2025 | Compensation for services other than consulting (speaking, faculty) APRETUDE · HIV | $1,300 |
| Viiv Healthcare Company Mar 11, 2025 | Travel and Lodging CABENUVA · HIV · travel to Fort Worth, TX | $76.60 |
| Viiv Healthcare Company Mar 4, 2025 | Compensation for services other than consulting (speaking, faculty) APRETUDE · HIV | $2,600 |
| Viiv Healthcare Company Feb 28, 2025 | Travel and Lodging travel to Hollywood, FL · in-kind | $472 |
| Gilead Sciences, Inc. Feb 22, 2025 | Consulting FeeCompany’s description;4296470;GTF;11531624 | $1,750 |
| Viiv Healthcare Company Feb 13, 2025 | Travel and Lodging APRETUDE · HIV · travel to Houston, TX · in-kind | $380 |
| Viiv Healthcare Company Feb 13, 2025 | Travel and Lodging APRETUDE · HIV · travel to Houston, TX · in-kind | $188 |
| Viiv Healthcare Company Feb 6, 2025 | Travel and Lodging APRETUDE · HIV · travel to San Antonio, TX · in-kind | $1,019 |
| Viiv Healthcare Company Feb 6, 2025 | Travel and Lodging APRETUDE · HIV · travel to San Antonio, TX · in-kind | $187 |
| Merck Sharp & Dohme LLC Feb 5, 2025 | Compensation for services other than consulting (speaking, faculty) PIFELTRO · INFECTIOUS DISEASE | $5,220 |
| Merck Sharp & Dohme LLC Feb 5, 2025 | Travel and Lodging PIFELTRO · INFECTIOUS DISEASE · travel to LOS ANGELES, CA | $150 |
| Merck Sharp & Dohme LLC Jan 24, 2025 | Travel and Lodging PIFELTRO · INFECTIOUS DISEASE · travel to LOS ANGELES, CA · in-kind | $439 |
| Merck Sharp & Dohme LLC Jan 24, 2025 | Travel and Lodging PIFELTRO · INFECTIOUS DISEASE · travel to LOS ANGELES, CA · in-kind | $378 |
| Merck Sharp & Dohme LLC Jan 24, 2025 | Travel and Lodging PIFELTRO · INFECTIOUS DISEASE · travel to LOS ANGELES, CA · in-kind | $224 |
| Viiv Healthcare Company Jan 22, 2025 | Travel and Lodging travel to Hollywood, FL · in-kind | $554 |
| Viiv Healthcare Company Jan 22, 2025 | Travel and Lodging travel to Hollywood, FL · in-kind | $31.02 |
| Viiv Healthcare Company Jan 3, 2025 | Compensation for services other than consulting (speaking, faculty) APRETUDE · HIV | $3,900 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $287,151 in research payments for these studies, mostly to the institutions running them.
- Study name not reported
Roche Molecular Systems, Inc. - M19-965 - A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of…
AbbVie Inc. - Study to Evaluate Sampling Methods for Detection of Human Papillomavirus HPV in the Anogenital Region of Males
Merck Sharp & Dohme LLC - A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382
AbbVie Inc. · Terminated · NCT06032546
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.